GBI Research, the leading business intelligence provider, has released its latest research, “Orphan Autoimmune Disorders to 2017 – Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market”.
It provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders therapeutics market. The report analyzes the markets for orphan autoimmune disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographies as well as the leading therapeutic segments (ITP, myasthenia gravis and ALS). Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The orphan autoimmune disorder therapeutics market is one of the steadily growing markets in autoimmune therapeutics and is expected to show a significant growth in forecast period. The ITP and ALS market are the leading contributors to the global orphan autoimmune disorder therapeutics market in 2010. Moreover, the market for myasthenia gravis has shown a steady growth in terms of revenue and is expected to grow at a greater pace in the future.
Orphan Autoimmune Disorders, Global, Revenue ($m), 2002- 2017
The ITP market has witnessed a significant growth between 2008 and 2010 due to the launch of two novel second-line therapies, namely Nplate (romiplostim) and Promacta (eltrombopag), which stimulate platelet production in adults with chronic ITP. The ALS market has also shown a steady growth in terms of revenue in the presence of Rilutek, which is the only FDA approved drug for this indication. The myasthenia gravis market is dominated by generics and over-the-counter (OTC) drugs. However the approval of Prograf (tacrolimus hydrate) in Japan (October 2009) and the future launch of Venoglobulin-IH, a human immunoglobulin therapy is expected to boost the myasthenia gravis market in the forecasted period.
The Idiopathic Thrombocytopenic Purpura (ITP) Market is the Major Contributor to the Orphan Autoimmune Disorders Therapeutics Market
Low Prevalence Rates of Orphan Autoimmune Disorders Affect the Market Size and Growth
Stiff Competition from Generics and Off-Label Products is Restraining the Growth of the Orphan Autoimmune Disorders Therapeutics Market
In ITP and ALS markets ’branded drugs’ take a significant market share. However the late-stage R&D pipelines for orphan autoimmune disorders principally comprises immunoglobulin therapies, a few corticosteroids and immunosuppressants. All these factors, coupled with lack of novel molecules in the pipeline, could be a major restraint to the market.
To order this report or find out more visit GBI Research.